Mihajlo Ceraj Ceri, Life Sciences Director, and Marijo Volarevi, VP Business Services at Infotehna, investigate how generic drug manufacturers can benefit utilising document management solutions in managing the drug development process.
Pierre-Olivier Tremblay, Associate Director of Pharmacometrics Clinical Pharmacology at Pharmanet l3, describes how pharmacometrics uses the application of mathematics to analyse vast amounts of data about disease progression, drug response, and clinical behaviour.
Discovery scientists continually seek better data earlier to rapidly assess whether a new compound will be both effective and safe. Generating relevant in vivo data earlier that minimises the number of animals, the time and the costs would be an asset to a discovery group.
Pharmacokinetics and pharmacodynamics are disciplines that can straddle discovery and development when considered in their complex physiologic relationship to one another using a
sophisticated PK/PD model. Richard Slauter, Senior Director of Drug Metabolism/Pharmacokinetics and Senior Principal Study Director at MPI Research, describes how traditionally pharmacokinetics is placed in the preclinical discovery phase, because it is a series of studies that helps to narrow the number of molecules being evaluated for a particular therapeutic approach.